[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:primary-central-nervous-system-lymphoma:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Primary Central Nervous System Lymphoma","CD19 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[12],"Phase 1","RECRUITING","2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[20],"Phase 2","2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT03666000","Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed\u002FRefractory (r\u002Fr) Non-Hodgkin Lymphoma (NHL) and r\u002Fr B-cell Acute Lymphoblastic Leukemia (B-ALL)",[12],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:27.435593Z"]